During natalizumab treatment of MS patients, there was an increase in the expression of TBX21, RORC, IFNγ, and IL-17A, and a decrease in the expression of FOXP3 in CD49d+ memory CD4 T cells. Here, IL17A is linked to myeloid sarcoma.